Yun Zhong
Stock Analyst at Wedbush
(1.50)
# 3,341
Out of 4,944 analysts
35
Total ratings
48.39%
Success rate
-10.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMT Sagimet Biosciences | Initiates: Outperform | $28 | $9.80 | +185.71% | 1 | Aug 11, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $212 → $220 | $190.02 | +15.78% | 2 | Aug 8, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Outperform | $9 → $8 | $3.66 | +118.58% | 2 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Reiterates: Outperform | $18 | $8.76 | +105.48% | 1 | Jun 23, 2025 | |
| KROS Keros Therapeutics | Reiterates: Neutral | $15 | $13.93 | +7.68% | 2 | May 30, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $8 | $1.40 | +471.43% | 1 | May 27, 2025 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Outperform | $32 | $3.14 | +919.11% | 2 | May 16, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $70 | $56.00 | +25.00% | 2 | Mar 28, 2025 | |
| PASG Passage Bio | Assumes: Outperform | $80 | $5.98 | +1,238.91% | 2 | Nov 29, 2024 | |
| MLTX MoonLake Immunotherapeutics | Assumes: Outperform | $92 → $73 | $55.16 | +32.34% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $6.34 | +89.42% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $10.73 | +160.95% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.02 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $7.16 | +123.62% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $160 | $19.43 | +723.47% | 11 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $14.52 | +216.80% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.74 | +474.71% | 1 | May 5, 2021 |
Sagimet Biosciences
Aug 11, 2025
Initiates: Outperform
Price Target: $28
Current: $9.80
Upside: +185.71%
Ascendis Pharma
Aug 8, 2025
Maintains: Outperform
Price Target: $212 → $220
Current: $190.02
Upside: +15.78%
Voyager Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $3.66
Upside: +118.58%
Wave Life Sciences
Jun 23, 2025
Reiterates: Outperform
Price Target: $18
Current: $8.76
Upside: +105.48%
Keros Therapeutics
May 30, 2025
Reiterates: Neutral
Price Target: $15
Current: $13.93
Upside: +7.68%
Camp4 Therapeutics
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $1.40
Upside: +471.43%
Rocket Pharmaceuticals
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $3.14
Upside: +919.11%
Protagonist Therapeutics
Mar 28, 2025
Reiterates: Outperform
Price Target: $70
Current: $56.00
Upside: +25.00%
Passage Bio
Nov 29, 2024
Assumes: Outperform
Price Target: $80
Current: $5.98
Upside: +1,238.91%
MoonLake Immunotherapeutics
Nov 5, 2024
Assumes: Outperform
Price Target: $92 → $73
Current: $55.16
Upside: +32.34%
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $6.34
Upside: +89.42%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $10.73
Upside: +160.95%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.02
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $7.16
Upside: +123.62%
Dec 22, 2022
Maintains: Buy
Price Target: $125 → $160
Current: $19.43
Upside: +723.47%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $14.52
Upside: +216.80%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $1.74
Upside: +474.71%